The Accelerating Clinical Trials (ACT) consortium, through an independent, international review panel, has selected CanReview to set up, initiate, and conduct a pan-Canadian single REB review and approval process with strict timelines.
Currently, researchers who wish to conduct a multi-centre randomized controlled trial (RCT) across Canada are required to get multiple research ethics board (REB) approvals across the different research centres. As part of Canada’s mandate to improve the ecosystem for conducting clinical trials in Canada, ACT held an open competition to select a group to set up and run a sustainable pan-Canadian, distributive, single REB review and approval process with strict timelines for the initiation and conduct of multi-centre RCTs in Canada.
Clinical Trials Ontario (CTO) congratulates and celebrates with members of the CanReview collaboration in being selected to move this important work forward for the benefit of all people in Canada.
Working collaboratively with Research Ethics Boards, research teams, Indigenous community members, institutions and sponsors, patients and family partners and many others, CanReview will co-develop a system that will:
- Improve efficiencies and study start-up times
- Increase Canada’s competitiveness in attracting global clinical trials
- Expand clinical trials to underserved and rural and remote locations
- Improve equitable access to trial participation
CTO looks forward to supporting CanReview by offering expertise on the collaboration’s Leadership Team, and by leveraging CTO Stream, an adaptable web-based platform for single research ethics review that has managed more than 2,500 multi-site studies and supported nearly 10,000 users since 2015.